OSLO, Norway--(BUSINESS WIRE)--Curida Holding AS (“Curida”) has announced a significant growth investment from Signet Healthcare Partners (“Signet”), a New York-based healthcare private equity firm. This strategic partnership will enable Curida to accelerate its expansion plans, including enhancing facility capabilities and growing its industry position..

挪威奥斯陆——（商业新闻短讯）——Curida Holding AS（“Curida”）宣布，总部位于纽约的医疗保健私人股本公司Signet Healthcare Partners（“Signet”）将对其进行重大增长投资。这种战略合作关系将使库里达加快其扩张计划，包括增强设施能力和提高其行业地位。

Established in 2015 and headquartered in Oslo, Norway, Curida is an integrated Contract Development and Manufacturing Organization (“CDMO”) specializing in the use of blow-fill-seal (“BFS”) and nasal spray technologies, as well as antibody manufacturing. Curida provides outsourced development and manufacturing of aseptic and non-aseptic liquid BFS and nasal spray formatted drugs, and serves the diagnostics industry with monoclonal antibodies.

库里达成立于2015年，总部位于挪威奥斯陆，是一家综合合同开发和制造组织（“CDMO”），专业从事吹填密封（“BFS”）和鼻喷雾剂技术的使用以及抗体制造。库里达提供无菌和非无菌液体BFS和鼻喷雾剂成型药物的外包开发和制造，并为诊断行业提供单克隆抗体服务。

Curida’s customer base ranges from small to medium-sized pharmaceutical, medical devices, and biotech companies, delivering solutions in drug development and GMP manufacturing globally..

库里达的客户群涵盖中小型制药、医疗器械和生物技术公司，在全球范围内提供药物开发和GMP制造解决方案。

In conjunction with Signet’s investment, Signet is joining the Board of Directors, and Ole J. Dahlberg has been appointed as Chairman of the Board. Dahlberg has more than 20 years of experience from leadership roles in the life science market and is former Vice President & General Manager at Thermo Fisher Scientific in California, USA.

随着Signet的投资，Signet加入了董事会，OleJ.Dahlberg被任命为董事会主席。Dahlberg拥有20多年的生命科学市场领导经验，曾任美国加利福尼亚州Thermo Fisher Scientific公司副总裁兼总经理。

Dahlberg stated, “We are very pleased to welcome Signet as a significant shareholder in Curida. Signet brings strong relevant industry experience and a track record of CDMO investing. Signet is co-investing alongside Curida’s existing shareholders Canica, Investinor, Klaveness, and Farvatn. We are excited by the opportunity to further accelerate innovation and advance productivity for our pharma and biotech customers in their work to deliver medicines and therapeutics to benefit patients.

Dahlberg表示：“我们非常高兴地欢迎Signet成为库里达的重要股东。Signet带来了丰富的相关行业经验和CDMO投资记录。Signet与库里达现有股东Canica、Investinor、Klaveness和Farvatn共同投资。我们很高兴有机会进一步加快创新，提高我们的制药和生物技术客户的生产力，为患者提供药物和治疗。

On behalf of the board, I want to thank Per Thoresen, who has been acting Chairman of the Board and for his valuable contributions to Curida over the past 9 years.”.

我谨代表董事会感谢佩尔·索雷森（Per Thoresen），他一直担任董事会代理主席，并在过去9年中为库里达做出了宝贵贡献。”

Additionally, the Board has appointed Anders Larsson, the Company’s Chief Operating Officer, as Chief Executive Officer, effective May 1st, 2024. Larsson comes with extensive experience in management, operations, and strategic development from the pharma industry. His former roles include CEO of Boots Pharmacy/Alliance Healthcare in Norway (Cencora).

此外，董事会已任命公司首席运营官安德斯·拉尔森（Anders Larsson）为首席执行官，自2024年5月1日起生效。拉尔森在制药行业拥有丰富的管理、运营和战略发展经验。他以前的角色包括挪威Boots Pharmacy/Alliance Healthcare（Cencora）的首席执行官。

In addition, Larsson has experience from various roles in the food & beverage industry with Orkla and Carlsberg. Larsson holds an MSc in Chemical Engineering from Chalmers University and Imperial College and a BSc in Finance from Gothenburg University..

此外，Larsson拥有与Orkla和Carlsberg在食品和饮料行业担任各种角色的经验。Larsson拥有查尔默斯大学和帝国理工学院的化学工程硕士学位，以及哥德堡大学的金融理学学士学位。

Signet Managing Director Nikhil Puri said, “We are proud to partner with Curida and support their robust growth strategy. The Company’s strong values, commitment to excellence, and strategic vision align nicely with our investment philosophy. We look forward to contributing to Curida’s success in the coming years.

Signet董事总经理Nikhil Puri表示：“我们很荣幸与库里达合作，并支持其稳健的增长战略。该公司强大的价值观、追求卓越的承诺和战略愿景与我们的投资理念非常吻合。我们期待着在未来几年为库里达的成功做出贡献。

We were attracted to Curida due to its strong, differentiated manufacturing capabilities, customer-centric approach, and management team strength. We see a strong opportunity for Signet to leverage its network and prior CDMO investment experience to accelerate growth.”.

库里达强大、差异化的制造能力、以客户为中心的方法和管理团队实力吸引了我们。我们认为Signet有很好的机会利用其网络和之前的CDMO投资经验来加速增长。”

DNB Markets served as financial advisor, and Advokatfirmaet Simonsen Vogt Wiig served as legal advisor to Curida. Sheppard, Mullin, Richter & Hampton LLP and Advokatfirmaet Selmer served as legal advisors to Signet. Terms of the transaction were not disclosed.

DNB Markets担任财务顾问，Advokatfirmaet Simonsen Vogt Wiig担任Curida的法律顾问。Sheppard、Mullin、Richter&Hampton LLP和Advokatfirmaet Selmer担任Signet的法律顾问。交易条款未披露。

About Curida Group

关于库里达集团

Curida offers contract development and manufacturing solutions to European pharmaceutical and biotech companies globally. Curida focuses on aseptic and non-aseptic liquid manufacturing and specializes in blow-fill-seal (“BFS”) and nasal spray technologies to serve the Small Molecules pharmaceutical and medical device market.

库里达为全球的欧洲制药和生物技术公司提供合同开发和制造解决方案。库里达专注于无菌和非无菌液体制造，专门从事吹填密封（“BFS”）和鼻喷雾剂技术，以服务于小分子制药和医疗器械市场。

For biologics, Curida offers upstream- and downstream processing of monoclonal antibodies for in-vitro diagnostics (“IVD”). For more information, visit www.curida.no.

对于生物制剂，库里达为体外诊断（“IVD”）提供单克隆抗体的上游和下游加工。欲了解更多信息，请访问www.curida.no。

About Signet Healthcare Partners

关于Signet Healthcare Partners

Headquartered in New York, NY, Signet is an established provider of growth capital to innovative healthcare companies. SIGNET invests in commercial-stage healthcare companies that are revenue generating or preparing for commercial launch. The firm invests primarily in pharmaceutical and medical device companies.

Signet总部位于纽约州纽约市，是一家为创新型医疗保健公司提供增长资本的成熟供应商。SIGNET投资于商业阶段的医疗保健公司，这些公司正在产生收入或准备商业启动。该公司主要投资于制药和医疗器械公司。

As an active investor, Signet partners closely with its companies to build their value including facilitating activities between portfolio companies. During Signet's 25-year history, the firm has developed a strong reputation and track record of successful healthcare investments. Signet has raised funds with total capital commitments of over $600 million and has invested in more than 55 companies.

作为一名积极的投资者，Signet与其公司密切合作，以建立其价值，包括促进投资组合公司之间的活动。在Signet 25年的历史中，该公司在成功的医疗保健投资方面建立了良好的声誉和记录。Signet已筹集资金，总资本承诺超过6亿美元，并投资了55多家公司。

For more information, visit www.signethealthcarepartners.com..

For more information, visit www.signethealthcarepartners.com..